The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Outlook 2024

Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Outlook 2024

Publishing Date : Nov, 2021

License Type :
 

Report Code : 1632273

No of Pages : 118

Synopsis
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the space surrounding the brain.
The global aneurysmal subarachnoid hemorrhage drugs market is segmented based on drug class and region. Based on drug class, the market is segmented into opioid analgesic, calcium channel blocker, anticonvulsant, stool softener, osmotic agent/diuretic, and other drugs.

The global Aneurysmal Subarachnoid Hemorrhage Drugs market was valued at US$ 150.5 million in 2020 and is expected to reach US$ 178.8 million by the end of 2027, growing at a CAGR of 2.0% during 2021-2027.
This report focuses on Aneurysmal Subarachnoid Hemorrhage Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Aneurysmal Subarachnoid Hemorrhage Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Aneurysmal Subarachnoid Hemorrhage Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Opioid Analgesic
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agent
  • Other Drugs

Segment by Application

  • Hospital
  • Clinic
  • Others

Consumption by Region

  • North America (United States, Canada, Mexico)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, Other Regions)
  • Europe (Germany, U.K., France, Italy, Russia, Rest of Europe)
  • South America (Brazil, Argentina, Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, U.A.E., South Africa, Other Regions)

By Company

  • Arbor Pharmaceuticals
  • PDS Biotechnology Corporation
  • Johnson and Johnson
  • Mylan N.V
  • Orexo AB
  • Pfizer
  • Purdue Pharma
  • Pharmaxis
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical

Scope of the Aneurysmal Subarachnoid Hemorrhage Drugs Market Report

Report Metric

Details

Report Name

Aneurysmal Subarachnoid Hemorrhage Drugs Market

Market size in 2021

US$ 150.5 Million

The revenue forecast in 2027

US$ 178.8 Million

Growth Rate

CAGR of 2.0% from 2021 to 2027

Market size available for years

2020-2027

Forecast units

Value (USD) & Volume (Units)

Segments covered

Types, End-User / Applications, Companies, and Region

Report coverage

Revenue & volume forecast, company share, competitive landscape, growth factors, and trends

Geographic regions covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

Index

1 Aneurysmal Subarachnoid Hemorrhage Drugs Market Overview
1.1 Product Overview and Scope of Aneurysmal Subarachnoid Hemorrhage Drugs
1.2 Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Type
1.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Opioid Analgesic
1.2.3 Calcium Channel Blocker
1.2.4 Anticonvulsant
1.2.5 Stool Softener
1.2.6 Osmotic Agent
1.2.7 Other Drugs
1.3 Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Application
1.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size Estimates and Forecasts
1.4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue 2016-2027
1.4.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales 2016-2027
1.4.3 Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Aneurysmal Subarachnoid Hemorrhage Drugs Market Competition by Manufacturers
2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturing Sites, Area Served, Product Type
2.5 Aneurysmal Subarachnoid Hemorrhage Drugs Market Competitive Situation and Trends
2.5.1 Aneurysmal Subarachnoid Hemorrhage Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Aneurysmal Subarachnoid Hemorrhage Drugs Players Market Share by Revenue
2.5.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Aneurysmal Subarachnoid Hemorrhage Drugs Retrospective Market Scenario by Region
3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
3.3.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country
3.3.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
3.4.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country
3.4.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region
3.5.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
3.6.1 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country
3.6.2 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country
3.7.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Historic Market Analysis by Type
4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2016-2021)
4.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Price by Type (2016-2021)

5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Historic Market Analysis by Application
5.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2016-2021)
5.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Arbor Pharmaceuticals
6.1.1 Arbor Pharmaceuticals Corporation Information
6.1.2 Arbor Pharmaceuticals Description and Business Overview
6.1.3 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.1.5 Arbor Pharmaceuticals Recent Developments/Updates
6.2 PDS Biotechnology Corporation
6.2.1 PDS Biotechnology Corporation Corporation Information
6.2.2 PDS Biotechnology Corporation Description and Business Overview
6.2.3 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.2.5 PDS Biotechnology Corporation Recent Developments/Updates
6.3 Johnson and Johnson
6.3.1 Johnson and Johnson Corporation Information
6.3.2 Johnson and Johnson Description and Business Overview
6.3.3 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.3.5 Johnson and Johnson Recent Developments/Updates
6.4 Mylan N.V
6.4.1 Mylan N.V Corporation Information
6.4.2 Mylan N.V Description and Business Overview
6.4.3 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.4.5 Mylan N.V Recent Developments/Updates
6.5 Orexo AB
6.5.1 Orexo AB Corporation Information
6.5.2 Orexo AB Description and Business Overview
6.5.3 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.5.5 Orexo AB Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Purdue Pharma
6.6.1 Purdue Pharma Corporation Information
6.6.2 Purdue Pharma Description and Business Overview
6.6.3 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.7.5 Purdue Pharma Recent Developments/Updates
6.8 Pharmaxis
6.8.1 Pharmaxis Corporation Information
6.8.2 Pharmaxis Description and Business Overview
6.8.3 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.8.5 Pharmaxis Recent Developments/Updates
6.9 Sun Pharmaceutical Industries
6.9.1 Sun Pharmaceutical Industries Corporation Information
6.9.2 Sun Pharmaceutical Industries Description and Business Overview
6.9.3 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.9.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.10 Teva Pharmaceutical
6.10.1 Teva Pharmaceutical Corporation Information
6.10.2 Teva Pharmaceutical Description and Business Overview
6.10.3 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
6.10.5 Teva Pharmaceutical Recent Developments/Updates

7 Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturing Cost Analysis
7.1 Aneurysmal Subarachnoid Hemorrhage Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Aneurysmal Subarachnoid Hemorrhage Drugs
7.4 Aneurysmal Subarachnoid Hemorrhage Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Aneurysmal Subarachnoid Hemorrhage Drugs Distributors List
8.3 Aneurysmal Subarachnoid Hemorrhage Drugs Customers

9 Aneurysmal Subarachnoid Hemorrhage Drugs Market Dynamics
9.1 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends
9.2 Aneurysmal Subarachnoid Hemorrhage Drugs Growth Drivers
9.3 Aneurysmal Subarachnoid Hemorrhage Drugs Market Challenges
9.4 Aneurysmal Subarachnoid Hemorrhage Drugs Market Restraints

10 Global Market Forecast
10.1 Aneurysmal Subarachnoid Hemorrhage Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Aneurysmal Subarachnoid Hemorrhage Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Aneurysmal Subarachnoid Hemorrhage Drugs by Type (2022-2027)
10.2 Aneurysmal Subarachnoid Hemorrhage Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Aneurysmal Subarachnoid Hemorrhage Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Aneurysmal Subarachnoid Hemorrhage Drugs by Application (2022-2027)
10.3 Aneurysmal Subarachnoid Hemorrhage Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Aneurysmal Subarachnoid Hemorrhage Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Aneurysmal Subarachnoid Hemorrhage Drugs by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT) Comparison by Application (2021-2027)
Table 3. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Covered in This Study
Table 5. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT) of Key Manufacturers (2016-2021)
Table 6. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Aneurysmal Subarachnoid Hemorrhage Drugs Average Price (USD/MT) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Aneurysmal Subarachnoid Hemorrhage Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Aneurysmal Subarachnoid Hemorrhage Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2016-2021) & (K MT)
Table 16. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2016-2021) & (K MT)
Table 19. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2016-2021) & (K MT)
Table 23. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2016-2021) & (K MT)
Table 27. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2016-2021) & (K MT)
Table 31. Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2016-2021) & (K MT)
Table 35. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT) by Type (2016-2021)
Table 39. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Type (2016-2021)
Table 42. Global Aneurysmal Subarachnoid Hemorrhage Drugs Price (USD/MT) by Type (2016-2021)
Table 43. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT) by Application (2016-2021)
Table 44. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Application (2016-2021)
Table 47. Global Aneurysmal Subarachnoid Hemorrhage Drugs Price (USD/MT) by Application (2016-2021)
Table 48. Arbor Pharmaceuticals Corporation Information
Table 49. Arbor Pharmaceuticals Description and Business Overview
Table 50. Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 51. Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 52. Arbor Pharmaceuticals Recent Developments/Updates
Table 53. PDS Biotechnology Corporation Corporation Information
Table 54. PDS Biotechnology Corporation Description and Business Overview
Table 55. PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 56. PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 57. PDS Biotechnology Corporation Recent Developments/Updates
Table 58. Johnson and Johnson Corporation Information
Table 59. Johnson and Johnson Description and Business Overview
Table 60. Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 61. Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 62. Johnson and Johnson Recent Developments/Updates
Table 63. Mylan N.V Corporation Information
Table 64. Mylan N.V Description and Business Overview
Table 65. Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 66. Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 67. Mylan N.V Recent Developments/Updates
Table 68. Orexo AB Corporation Information
Table 69. Orexo AB Description and Business Overview
Table 70. Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 71. Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 72. Orexo AB Recent Developments/Updates
Table 73. Pfizer Corporation Information
Table 74. Pfizer Description and Business Overview
Table 75. Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 76. Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 77. Pfizer Recent Developments/Updates
Table 78. Purdue Pharma Corporation Information
Table 79. Purdue Pharma Description and Business Overview
Table 80. Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 81. Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 82. Purdue Pharma Recent Developments/Updates
Table 83. Pharmaxis Corporation Information
Table 84. Pharmaxis Description and Business Overview
Table 85. Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 86. Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 87. Pharmaxis Recent Developments/Updates
Table 88. Sun Pharmaceutical Industries Corporation Information
Table 89. Sun Pharmaceutical Industries Description and Business Overview
Table 90. Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 91. Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 92. Sun Pharmaceutical Industries Recent Developments/Updates
Table 93. Teva Pharmaceutical Corporation Information
Table 94. Teva Pharmaceutical Description and Business Overview
Table 95. Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 96. Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Product
Table 97. Teva Pharmaceutical Recent Developments/Updates
Table 98. Production Base and Market Concentration Rate of Raw Material
Table 99. Key Suppliers of Raw Materials
Table 100. Aneurysmal Subarachnoid Hemorrhage Drugs Distributors List
Table 101. Aneurysmal Subarachnoid Hemorrhage Drugs Customers List
Table 102. Aneurysmal Subarachnoid Hemorrhage Drugs Market Trends
Table 103. Aneurysmal Subarachnoid Hemorrhage Drugs Growth Drivers
Table 104. Aneurysmal Subarachnoid Hemorrhage Drugs Market Challenges
Table 105. Aneurysmal Subarachnoid Hemorrhage Drugs Market Restraints
Table 106. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Type (2022-2027) & (K MT)
Table 107. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share Forecast by Type (2022-2027)
Table 108. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 109. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 110. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Application (2022-2027) & (K MT)
Table 111. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share Forecast by Application (2022-2027)
Table 112. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 113. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 114. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Region (2022-2027) & (K MT)
Table 115. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share Forecast by Region (2022-2027)
Table 116. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 117. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Aneurysmal Subarachnoid Hemorrhage Drugs
Figure 2. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Share by Type in 2020 & 2027
Figure 3. Opioid Analgesic Product Picture
Figure 4. Calcium Channel Blocker Product Picture
Figure 5. Anticonvulsant Product Picture
Figure 6. Stool Softener Product Picture
Figure 7. Osmotic Agent Product Picture
Figure 8. Other Drugs Product Picture
Figure 9. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Share by Application in 2020 & 2027
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size 2016-2027 (US$ Million)
Figure 15. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales 2016-2027 (K MT)
Figure 16. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 17. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Share by Manufacturers in 2020
Figure 18. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Manufacturers in 2020
Figure 19. The Global 5 and 10 Largest Aneurysmal Subarachnoid Hemorrhage Drugs Players: Market Share by Revenue in 2020
Figure 20. Aneurysmal Subarachnoid Hemorrhage Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 21. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region (2016-2021)
Figure 22. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region in 2020
Figure 23. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Region (2016-2021)
Figure 24. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Region in 2020
Figure 25. U.S. Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. France Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Russia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. China Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. India Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Australia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Taiwan Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Indonesia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Thailand Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Malaysia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Philippines Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Vietnam Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. U.A.E Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Sales Market Share of Aneurysmal Subarachnoid Hemorrhage Drugs by Type (2016-2021)
Figure 50. Sales Market Share of Aneurysmal Subarachnoid Hemorrhage Drugs by Application (2016-2021)
Figure 51. Sales Market Share of Aneurysmal Subarachnoid Hemorrhage Drugs by Application in 2020
Figure 52. Revenue Share of Aneurysmal Subarachnoid Hemorrhage Drugs by Application (2016-2021)
Figure 53. Revenue Share of Aneurysmal Subarachnoid Hemorrhage Drugs by Application in 2020
Figure 54. Manufacturing Cost Structure of Aneurysmal Subarachnoid Hemorrhage Drugs
Figure 55. Manufacturing Process Analysis of Aneurysmal Subarachnoid Hemorrhage Drugs
Figure 56. Aneurysmal Subarachnoid Hemorrhage Drugs Industrial Chain Analysis
Figure 57. Channels of Distribution
Figure 58. Distributors Profiles
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’